MA35865B1 - Formulations pharmaceutiques stabilisées d'un inhibiteur du vhc puissant - Google Patents

Formulations pharmaceutiques stabilisées d'un inhibiteur du vhc puissant

Info

Publication number
MA35865B1
MA35865B1 MA37207A MA37207A MA35865B1 MA 35865 B1 MA35865 B1 MA 35865B1 MA 37207 A MA37207 A MA 37207A MA 37207 A MA37207 A MA 37207A MA 35865 B1 MA35865 B1 MA 35865B1
Authority
MA
Morocco
Prior art keywords
vhc
pharmaceutical formulations
inhibitor
potent
control
Prior art date
Application number
MA37207A
Other languages
English (en)
French (fr)
Inventor
Mathias Braun
Carl Alan Busacca
Feng-Jing Chen
Edwin Louis Gump
Jenness B Majeska
Scott Pennino
Fenghe Qiu
Maria Fernanda Villagra
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47628447&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA35865(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of MA35865B1 publication Critical patent/MA35865B1/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06Tripeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA37207A 2012-01-12 2014-07-11 Formulations pharmaceutiques stabilisées d'un inhibiteur du vhc puissant MA35865B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261586087P 2012-01-12 2012-01-12
PCT/US2013/020934 WO2013106506A1 (en) 2012-01-12 2013-01-10 Stabilized pharmaceutical formulations of a potent hcv inhibitor

Publications (1)

Publication Number Publication Date
MA35865B1 true MA35865B1 (fr) 2014-12-01

Family

ID=47628447

Family Applications (1)

Application Number Title Priority Date Filing Date
MA37207A MA35865B1 (fr) 2012-01-12 2014-07-11 Formulations pharmaceutiques stabilisées d'un inhibiteur du vhc puissant

Country Status (27)

Country Link
US (2) US20140037719A1 (index.php)
EP (1) EP2802313A1 (index.php)
JP (1) JP2015503616A (index.php)
KR (1) KR20140109433A (index.php)
CN (1) CN104244926A (index.php)
AP (1) AP2014007760A0 (index.php)
AR (1) AR089710A1 (index.php)
AU (1) AU2013208024A1 (index.php)
BR (1) BR112014017058A8 (index.php)
CA (1) CA2861041A1 (index.php)
CL (1) CL2014001783A1 (index.php)
CO (1) CO7000774A2 (index.php)
EA (1) EA201400808A1 (index.php)
EC (1) ECSP14013104A (index.php)
HK (1) HK1204982A1 (index.php)
IL (1) IL233550A0 (index.php)
IN (1) IN2014DN05759A (index.php)
MA (1) MA35865B1 (index.php)
MX (1) MX2014008205A (index.php)
NZ (1) NZ626353A (index.php)
PE (1) PE20141817A1 (index.php)
PH (1) PH12014501598A1 (index.php)
SG (1) SG11201404042VA (index.php)
TN (1) TN2014000295A1 (index.php)
TW (1) TW201340969A (index.php)
UY (1) UY34569A (index.php)
WO (1) WO2013106506A1 (index.php)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA119315C2 (uk) 2012-07-03 2019-06-10 Гіліад Фармассет Елелсі Інгібітори вірусу гепатиту с
WO2014145095A1 (en) 2013-03-15 2014-09-18 Gilead Sciences, Inc. Macrocyclic and bicyclic inhibitors of hepatitis c virus

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5329976A (en) * 1991-12-09 1994-07-19 Habley Medical Technology Corporation Syringe-filling and medication mixing dispenser
US6323180B1 (en) 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
UY28240A1 (es) * 2003-03-27 2004-11-08 Boehringer Ingelheim Pharma Fases cristalinas de un potente inhibidor de la hcv
EP1654261B1 (en) 2003-05-21 2007-11-14 Boehringer Ingelheim International GmbH Hepatitis c inhibitor compounds
US7514557B2 (en) 2004-05-25 2009-04-07 Boehringer Ingelheim International Gmbh Process for preparing acyclic HCV protease inhibitors
WO2006130552A2 (en) * 2005-06-02 2006-12-07 Schering Corporation Methods of treating hepatitis c virus
MY153093A (en) 2008-09-16 2014-12-31 Boehringer Ingelheim Int Crystalline forms of a 2-thiazolyl-4-quinolinyl-oxy derivative, a potent hcv inhibitor
UA105777C2 (uk) * 2008-11-21 2014-06-25 Бьорінгер Інгельхайм Інтернаціональ Гмбх Фармацевтична композиція ефективного інгібітора вгс для перорального введення
KR101685941B1 (ko) 2009-07-07 2016-12-13 베링거 인겔하임 인터내셔날 게엠베하 C형 간염 바이러스 프로테아제 억제제를 위한 약제학적 조성물

Also Published As

Publication number Publication date
PH12014501598A1 (en) 2014-10-08
BR112014017058A2 (pt) 2017-06-13
BR112014017058A8 (pt) 2017-07-04
CN104244926A (zh) 2014-12-24
US20140037719A1 (en) 2014-02-06
JP2015503616A (ja) 2015-02-02
AU2013208024A1 (en) 2014-07-10
US20150190458A1 (en) 2015-07-09
CO7000774A2 (es) 2014-07-21
EP2802313A1 (en) 2014-11-19
AP2014007760A0 (en) 2014-07-31
IN2014DN05759A (index.php) 2015-04-10
UY34569A (es) 2013-07-31
AR089710A1 (es) 2014-09-10
KR20140109433A (ko) 2014-09-15
CA2861041A1 (en) 2013-07-18
SG11201404042VA (en) 2014-08-28
MX2014008205A (es) 2014-08-08
NZ626353A (en) 2016-02-26
CL2014001783A1 (es) 2014-12-12
EA201400808A1 (ru) 2015-02-27
TW201340969A (zh) 2013-10-16
PE20141817A1 (es) 2014-12-17
HK1204982A1 (en) 2015-12-11
ECSP14013104A (es) 2015-11-30
TN2014000295A1 (en) 2015-12-21
IL233550A0 (en) 2014-08-31
WO2013106506A1 (en) 2013-07-18

Similar Documents

Publication Publication Date Title
PH12018500960A1 (en) Processes for preparing isoquinolinones and solid forms of isoquinolinones
IL271927A (en) Pharmaceutical formulations containing rifaximin, processes for obtaining them and a method for treating intestinal disease
EA201071035A1 (ru) Фармацевтические композиции модифицированного высвобождения, содержащие микофенолат, и способ их получения
WO2012158945A3 (en) Compositions and methods for treating charcot-marie-tooth diseases and related neuronal diseases
PH12019502782A1 (en) Fixed dose formulations
ATE536172T1 (de) Ezetimibzusammensetzungen
WO2013003827A3 (en) Macrogol 15 hydroxystearate formulations
WO2014016754A3 (en) Pharmaceutical compositions of proton pump inhibitor
MD20150053A2 (ro) Produs de comicronizare cu conţinut de acetat de ulipristal
PH12017500029A1 (en) 4,5-dihydroisoxazole derivatives as nampt inhibitors
WO2013175494A3 (en) Controlled release pharmaceutical formulations of direct thrombin inhibitors
MX2013007661A (es) Derivados de fenil-isoxazol y procedimiento para la preparacion de los mismos.
MA35865B1 (fr) Formulations pharmaceutiques stabilisées d'un inhibiteur du vhc puissant
PT2247573E (pt) Sais carbónicos e de ácido sulfúrico de ésteres de 3-(2,2,2- trimetil-hidrazínio)propionato e sua utilização para a preparação de di-hidrato de 3-(2,2,2-trimetilhidrazínio) propionato
MY169266A (en) Solid state forms of n-((s)-2,3-dihydroxy-propyl)-3-(2-fluoro-4-iodo-phenylamino)-isonicotinamide
HK1258512A1 (zh) 芬坎法明的前药
PL3882244T3 (pl) ZWIĄZEK, JEGO FARMACEUTYCZNIE DOPUSZCZALNA SÓL LUB IZOMER OPTYCZNY, SPOSÓB ICH WYTWARZANIA i ZAWIERAJĄCA JE, JAKO SKŁADNIK AKTYWNY, KOMPOZYCJA FARMACEUTYCZNA DO PROFILAKTYKI LUB LECZENIA CHORÓB WIRUSOWYCH
CA2865484A1 (en) Stabilized controlled-release pharmaceutical composition comprising gliclazide
MX2017008931A (es) Formulaciones farmaceuticas de xantina o derivados de xantina.
PH12013502080A1 (en) Modified release pharmaceutical compositions of desvenlafaxine
WO2011115599A3 (en) Orally disintegrating tablet formulations of donepezil and process for preparing the same
WO2013168179A3 (en) Controlled release pharmaceutical formulations of antiviral agents
UA110882C2 (uk) Фармацевтична композиція та спосіб її отримання